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ABSTRACT 
 
 
Progress Toward the Synthesis of (+)-Dibromophakellin and Congeners: 
 
Proposed Final Stages for Palau’amine Synthesis.  (May 2007) 
 
Francisco Miguel Franco-Torres, B.S., Universidad de Puerto Rico 
 
San Juan, Puerto Rico 
 
Chair of Advisory Committee: Dr. Daniel Romo 
 
 
 The pyrrole-imidazole alkaloid family of natural products illustrates the diversity 
of topographically unique molecules with potent biological activities that can be found 
in the marine environment.  Thus, great interest for this class of compounds has 
developed leading to new synthetic methodologies and tactics to build these complex 
secondary metabolites. 
 The overall objectives of this research project include the total synthesis of the 
phakellins and phakellstatins.  First, we revisited the strategy developed in our group for 
the total synthesis of (+)-dibromophakellstatin and utilized it for the synthesis of its 
naturally occurring enantiomer and congeners.  Second, we proposed and studied a new 
and more concise approach to the phakellstatins and phakellins based on a key C-H 
insertion process developed by Du Bois. 
 
N
N
O
H
N
HN
X
N
N
O
NX
H2N
R
HC-H insertion
Mitsunobu
X = NH: pendant guanidine
X = O: pendant urea
X = NH: dibromophakellin
X = O: dibromophakellstatin
Br Br Br Br
FGA
N
N
O
HO
H
Br Br
Du Bois
 
iv 
 Attempts to streamline the first synthesis of (+)-dibromophakellstatin proved to 
be quite challenging.  Shortcomings in the reproducibility of some parts of the original 
strategy precluded us from completing and making more efficient the synthesis of the 
natural enantiomer (-)-dibromophakellstatin.  Fortuitously, our second generation 
approach though it presented itself as an efficient route to the phakellins and 
phakellstatins produced the undesired anti diastereomer of the key guanidine 
intermediate which precluded our study of the pivotal C-H insertion reaction. 
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1 
CHAPTER I 
 
AN INTRODUCTION TO THE SYNTHETIC AND BIOLOGICAL STUDIES 
 
OF THE TETRACYCLIC PYRROLE IMIDAZOLE ALKALOIDS  
 
PHAKELLINS, PHAKELLSTATINS, AND RELATED ISOLATES 
 
 
 
A.  Isolation and Biological Activity1 
 As the cradle of mankind, the natural world not only supports people’s needs, but 
also provides many novelties for study by organic chemists.  Every year, a considerable 
number of alkaloidal secondary metabolites are isolated from natural sources; some of 
these belong to known frameworks but others are completely new.  Several of these 
natural products have been extensively investigated because of their varying and often 
potent biological activities.  Many have lured chemists to pursue their total synthesis and 
the evaluation of their potential as chemotherapeutic agents.1  In fact, many of the anti-
HIV drugs (75%) and anti-cancer drugs (62%) currently used in chemotherapy either are 
derived directly from natural products or are derived from natural products leads (about 
52% of total drugs).2  Natural products that have potent and specific cellular effects have 
proven to be extremely useful as biochemical probes for dissecting molecular 
mechanisms of signal transduction pathways involved in various cellular functions. 
 Marine organisms are known producers of compounds with novel chemical 
structures and interesting biological activities.  The marine environment has proven to be 
a very rich source of extremely potent compounds that have demonstrated significant 
                                                 
1This thesis follows the style and format of the Journal of the American Chemical Society. 
2 
activities in anti-tumor, anti-inflammatory, analgesia, immunomodulation, allergy, and 
anti-viral assays.3  Among all the marine organisms studied to date, sponges have been, 
and still are, the most investigated for their incredible metabolite production.4  One class 
that are thought to be specifically derived from marine sponges and not symbiotic 
bacteria are the pyrrole-imidazole alkaloids.  These alkaloids are an interesting family of 
natural products.  An impressive number of these alkaloids have been isolated from 
different species of various families, mainly the Agelisidae, Axinellidae, and 
Hymeniacidonidae.5  The components of this family are fascinating due to their 
biogenetic relationship leading to a large, structurally diverse family presumed to be 
derived from a common key biosynthetic precursor, oroidin (1) (Figure 1).6 
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Figure 1.  Structure of oroidin (1), key metabolite to the pyrrole-imidazole alkaloids. 
 
 This family of alkaloids is composed of a diverse and complex class of bioactive 
secondary metabolites and only a few studies regarding their molecular mechanism of 
action have been reported.7  Novel examples with unprecedented molecular architecture 
and biological activities are constantly being discovered.  By the end of 2003, about 90 
pyrrole-imidazole alkaloids had been characterized, some of which occur in high 
concentrations of more than 1% of the sponge dry weight, or as low as 10-4%.8  Within 
3 
the family of the pyrrole-imidazole alkaloids are the phakellins, shown in Figure 2; these 
are cyclized monomers of oroidin (1). 
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Figure 2.  Structures of the phakellins and phakellstatins. 
 
 (-)-Dibromophakellin (2a) has been isolated from different sponges over 
different oceans.  Sharma and Burkholder first isolated it in 1969, along with (-)-
monobromophakellin (2b) and an unidentified antibacterial agent, from the marine 
sponge Phakellia flabellata at the Great Barrier Reef in Australia.9  Dibromophakellin 
(2a) has also been isolated from Phakellia mauritiana, alongside with (-)-
dibromophakellstatin (3a), off the coast of the Republic of Seychelles.10  It has also been 
isolated from the Fijian sponge Agelas mauritiana,11 from Stylotella aurantium in the 
Rock Islands, Republic of Belau,12 and from the algae Laurencia majuscula Lucas 
collected from the China Sea.13  Furthermore, (+)-dibromophakellin, the opposite 
enantiomer of 2a, was isolated from the marine sponge Pseudoaxinyssa cantharella 
garnered off the coast of New Caledonia.14 
 The structures of the brominated phakellins were elucidated by extensive 
analysis including NMR spectroscopy, IR spectroscopy, UV spectrophotometry, mass 
4 
spectrometry, and confirmed by X-ray analysis of the monoacetyl derivative of (-)-
dibromophakellin (2a).  These compounds, 2a and 2b, exhibit pKa values of < 8, which 
are rather low when compared to reported values for other guanidines with pKa > 13.4.9c  
This could be explained in terms of I-strain concepts.15  Theoretically, the basicity of a 
cyclic guanidine derivative will fall off rapidly due to departure from planarity of the 
CN3 skeleton that in the case of the phakellins will be due to the twisted conformation of 
the imidazoline ring, which will prevent delocalization of the pyrrole nitrogen lone pair 
into the guanidine moiety. 
 The phakellins possess several exotic features, among them we can mention the 
fact that the cyclic guanidine has the double bond in an endocyclic position, a feature 
rarely observed in this kind of moiety.  Also, both diaminoacetal (C6) and diaminoketal 
(C10) functionalities in the brominated phakellins are considerably stable toward 
hydrolytic agents.  Dibromophakellin (2a) and monobromophakellin (2b) were isolated 
as the hydrochloride salts from P. flabellata and they have shown mild antibacterial 
activity against Bacillus subtilis and Escherichia coli and mild antineoplastic activity 
(see Table 1, vide infra).9c  The responsible agent for the potent antibiotic activity in the 
crude methanol extracts of the sponge is due to some other substance(s) which has 
(have) not been identified yet.9c  Although (-)-phakellin (2c) has never been isolated 
from a natural source, it was semi-synthetically synthesized and until fairly recent the 
greater activity for the methanol extracts from P. flabellata had been tentatively 
attributed to phakellin based on the observation that palau’amine (4a) is more potent 
than its brominated derivatives (Figure 3).12   
5 
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Figure 3.  Structures of the palau’amines. 
 
 In 1997, Pettit and co-workers reported the isolation of (-)-dibromophakellstatin 
(3a), which differs from (-)-dibromophakellin (2a) by the replacement of the guanidine 
moiety for a urea, from Phakellia mauritiana as part of a bioassay-guided isolation 
procedure using human tumor cell lines (Figure 2, vide supra).  In fact, 
dibromophakellstatin (3a) was the most significant cancer cell growth inhibitory 
substance obtained from the natural source (Table 1). 
 
Table 1.  Cell growth inhibitory activity of dibromophakellin (2a) and 
dibromophakellstatin (3a) against a mini-panel of human cancer cell lines. 
ED50 (g/mL) Human Cancer Cell Line  Dibromophakellin Dibromophakellstatin 
Ovary, OVCAR-3 15.7 0.46 
Brain, SF-295 18.8 1.5 
Kidney, A498 17.8 0.21 
Lung, H460 22.0 0.62 
Colon, KM20L2 20.1 0.11 
Melanoma, SK-MEL-5 17.0 0.11 
 
 
6 
The structure of dibromophakellstatin (3a) was elucidated by NMR spectroscopic 
analysis (1H and 13C) comparison with dibromophakellin which resulted to be very 
similar and the molecular formula was deduced by HRFAB-MS.  The absolute 
stereochemistry was determined by single crystal X-ray analysis taking advantage of the 
pronounced anomalous dispersion effects induced by the bromine atoms. 
 A very interesting bromine-containing guanidine derivative from the C11-N5 
family, another way to refer to cyclized oroidin (1) monomers, was isolated from an 
Agelas sp. sponge in the coasts of Tanzania.  The novel dibromopyrrole derivative was 
named dibromoagelaspongine (5) and while being a typical representative for the 
pyrrole-imidazole alkaloids, possesses a different molecular skeletal structure though it 
seems to be biogenetically related to the phakellins (Figure 4).  Unambiguous 
elucidation of the structure of dibromoagelaspongine was achieved by X-ray analysis 
which revealed the highly uncommon ortho-imidine functionality at C15. 
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Figure 4.  Structures of dibromoagelaspongine (5), the isophakellins (6 and 7). 
 
 Previous to the isolation of dibromophakellstatin (3a), Maximov and co-workers 
described the isolation of (-)-dibromoisophakellin (6) from Acanthella carteri collected 
7 
off Madagascar (Figure 4).16  Careful spectroscopy analysis led to its characterization 
and it was found to be an A-ring isomer of dibromophakellin (2a).  The proposed 
structure was confirmed by crystallographic analysis.  Actually, the opposite enantiomer 
of dibromoisophakellin (5) was previously isolated from Pseudaxinyssa cantharella and 
named (+)-dibromocantharelline.14  Dibromoisophakellin (6), like its structural isomer 
dibromophakellin (2a), has been isolated from variety a marine sponges alongside with 
plethora of natural products, some known and some new.  One of those new metabolites 
is (-)-N-methyldibromoisophakellin (7) isolated from Stylissa caribica collected off the 
coast of Sweetings Cay, Bahamas (Figure 4).17  Bioassay-guided fractionation of the 
methanol extracts of this sponge looking for antifeedant properties resulted on the 
isolation and structural elucidation of isophakellin 7.  Its absolute configuration was 
determined by comparison of the optical rotation of N-methyldibromoisophakellin (7) 
with that of dibromoisophakellin (6).16  Interestingly, N-methyldibromoisophakellin (7) 
was shown to be the only secondary metabolite in Stylissa caribica that, at its natural 
concentration (0.9 mg/mL), is active as a feeding deterrent against a common 
omnivorous Caribbean reef fish, Thalassoma bifasciatum.   
 From the marine sponge Axinella brevistyla collected in western Japan was 
isolated 12-chloro-11-hydroxydibromoisophakellin (8) along with the known 
dibromoisophakellin (6) and other bromopyrrole alkaloids (Figure 5).18  A positive 
FABMS of isophakellin 8 displayed a 1:2:1.5:0.4 ion cluster at m/z 438/440/442/444, 
indicating the presence of a chlorine and two bromine atoms.  Its molecular formula of 
C11H11Br2ClN5O2 was obtained by HRFABMS.  COSY and HMBC experiments helped 
8 
in deciphering some of the key carbon-carbon connectivities on the molecule and 
NOESY cross-peaks from H6 to H11 and H12 suggested the relative stereochemistry of 
12-chloro-11-hydroxydibromoisophakellin (8) as shown in Figure 5.  12-chloro-11-
hydroxydibromoisophakellin (8) not only posses interesting skeletal features but also 
biological activities; in antifungal studies it showed growth inhibition of the erg6 mutant 
of the yeast Saccharomyces cerevisiae at 100 g/disk and also proved to be cytotoxic 
against L1210 cells with an IC50 value of 2.5 g/mL.   
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Figure 5.  Structures of 12-chloro-11-hydroxydibromoisophakellin (8) and ugibohlin 
(9). 
 
 Another member of the C11N5 family that was isolated along with 
dibromoisophakellin (6) is ugibohlin (9) (Figure 5).19  Isolated from Axinella carteri 
collected on a reed slope of Talakanen Island, Phillipines by Goetz and co-workers, 
ugibohlin (9) showed similar 1H and 13C NMR data to those of known compound 
dibromoisophakellin (6) and its enantiomer, dibromocantharelline.14,16  The 1H NMR 
spectrum of ugibohlin (9) lacked the methine signal (H6) found in the corresponding 
dibromoisophakellin (6) and dibromocantharelline.  This piece of evidence along with 
9 
the presence of two extra nonprotonated sp2 signals on the 13C NMR spectrum implied 
that ugibohlin (9) was the C10-N9 seco-derivative of dibromoisophakellin (6) or 
dibromocantharelline and that the C6-C10 bond was unsaturated. 
 Two new members of the phakellin family were reported by Crews and co-
workers, (-)-7-N-methyldibromophakellin (10a) and (-)-7-N-methylmonobromophakellin 
(10b), and their structures are shown in Figure 6.20  They were isolated from an 
undescribed Agelas sp. sponge collected near Wewak, Papua New Guinea, using a 
combination of bioassay- and LCMS-guided fractionation.  Their structure elucidation 
was completed by spectroscopic data analysis and comparison to the properties of the 
known phakellins.  The guided isolation assays were done employing both 12- and 15-
human lipoxygenase isozymes (12-HLO, 15-HLO).  (-)-7-N-methyldibromophakellin 
(10a) exhibited moderate selectivity towards 12-HLO (12-HLO IC50 = 10.7 ± 1.3 M; 
15-HLO IC50 = 48 ± 16 M).  12-HLO isozymes have been implicated in psoriasis and 
cancer cell proliferation via its role in the production of leukotrienes and lipoxins.21  (-)-
7-N-methylmonobromophakellin (10b) was not tested due to small sample amount.   
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Figure 6.  Structures of the N-methylbromophakellins. 
 
10 
 Recently, Al-Mourabit and co-workers isolated four new C11N5 metabolites from 
the Mediterranean sponge Axinella vaceleti.22  The verpacamides A-D, as they were 
named, are interesting bi- and tricyclic secondary metabolites which could potentially be 
derived from proline and arginine (i.e. verpacamide A) and further metabolized into the 
other verpacamides (Figure 7).  Verpacamides C (13) and D (14) are quite unique since 
these are the first examples of proline-proline-guanidine structures reported from marine 
sponges.  If verpacamides C and D are intriguing, even more so is the natural ring 
closure of the arginine in verpacamide B (12) into a guanidine-bearing proline 
functionality in verpacamide C (13) observed on this metabolite for the first time.  
Proline and arginine biosynthetic interconversion was only known via an ornithine 
intermediate.  
 
N
H
N
O
O
HH
NH
HN
H2N
N
H
N
O
O
H
NH
HN
H2N
N
N
O
O
H
NH
HN
H2N
N
N
O
O
H
NH
HN
H2N
MeO
HO
11: Verpacamide A 12: Verpacamide B 13: Verpacamide C 14: Verpacamide D
 
Figure 7.  Structures of the verpacamides A-D. 
 
B.  Biosynthetic Pathways 
 The biosynthetic machinery found in natural product producers has used very 
subtle chemistry based on the reactivity variation of a single precursor or a restricted 
number of precursors that under enzymatic-catalyzed primary and secondary metabolic 
11 
cycles produce a plethora of structural types.  The fascinating variety of secondary 
metabolites from the pyrrole-imidazole alkaloid family is not the exception since it 
contains some of the most unprecedented and intriguing molecules isolated from marine 
sponges.  Various speculative statements about the origin and mode of formation of the 
pyrrole-imidazole alkaloids have recently appeared in the literature. 
 
 1.  Biosynthetic Proposals 
 Al-Mourabit and Potier have proposed a plausible biogenetic mechanism that 
might help clarify the chemical pathway leading to over 90 polycyclic pyrrole-imidazole 
alkaloids.6  This hypothetical biogenetic pathway is an important step now that it may 
lead to new ideas for biomimetic total syntheses of this group of natural molecules.  
Within this group of alkaloids, it is easy to see that all derivatives are closely related, but 
still a logical chemical path to corroborate the presupposition of a common biogenesis is 
lacking.  The authors propose a very likely universal chemical conduit through simple 
precursors such as 3-amino-1-(2-aminoimidazolyl)-prop-1-ene (15) and 4,5-
dibromopyrrole-2-carboxylic acid (16) shown in Figure 8. 
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Figure 8.  Representative secondary metabolites from the pyrrole imidazole alkaloids. 
 
 Within their universal chemical outline, Al-Mourabit and Potier depicted the 
variety of modes of intramolecular cyclization that linear compounds, i.e. oroidin (1), 
can undergo to overcome various assemblies of polycyclic natural derivatives.  
Illustrated in Scheme 1 are three cyclization modes for the formation of 
dibromophakellin (2a), dibromoisophakellin (6), and dibromoagelaspongine (5). 
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 Based on the recent discovery of the verpacamides A-D (Figure 7, vide supra), 
Al-Mourabit and co-workers felt that these metabolites could potentially be early 
biosynthetic precursors of C11N5 derivatives.22  These diketopiperazines derivatives (11, 
12, or 13) may be considered as a combination of proline and arginine or proline-proline 
and guanidine and the first oxidized members in the pathway to transform the proline 
skeleton into pyrrole and 2-aminoimidazole derivatives (Scheme 2).  The supposed 
14 
cascade begins with the generation of cyclo(Pro-Arg) 11 and its further oxidation into a 
dioxetanone derivative such as 15.23  The driving force for the conversion to 
aminoimidazolone 16 would be the aromatization of one proline moiety into pyrrole and 
the intramolecular transfer of the guanidine.  Further transformations would lead to the 
essential precursors clathrodine (17) and oroidin (1), which as mentioned before play an 
important role in the production of more complex pyrrole-imidazole alkaloids. 
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 2.  Biosynthetic Studies 
 Biosynthetic investigations have been successful with plants and microorganisms 
by using cell cultures, however, this technique is particularly difficult to apply to marine 
invertebrates like marine sponges because of the intricacy on the establishment of viable 
and continuous cell lines.24  Other problems associated with biosynthetic studies of 
15 
marine organisms are (1) the complex organic extracts produced from the marine 
organism where the components of interest are present in minute quantities; (2) the rate 
of synthesis in vivo of the relevant metabolites is low and conditioned to seasonal and 
environmental variations; (3) the construction of artificial environments for marine 
sponges poses technical difficulties since marine invertebrates are filter feeders thus in 
their natural environment they digest bacteria and other particulate that the sea current 
might bring; (4) marine organisms commonly form symbiotic associations in their 
natural habitat; (5) the uptake and transport of precursors relative to the concentration of 
nutrients could work against a concentration gradient and uptake might not occur; and 
(6) studies in natural environments are almost impossible to do due to the uncontrollable 
nutrient supply to the animals.25  Despite all these factual experimental obstacles, Kerr 
and co-workers were able to establish reproducible primary cultures of Teichaxinella 
morchella archaeocytes to produce the bioactive metabolite stevensine (18).24  Their 
subsequent incorporation experiments utilizing the radiolabeled amino acids 14C-
histidine, 14C-arginine, 14C-ornithine, and 14C-proline showed that only 14C-histidine, 
14C-ornithine, and 14C-proline gave radioactive stevensine as shown by the percent 
incorporation of each amino acid in Table 2.  
 
Table 2.  Recovered radioactivity in stevensine (18). 
Labeled Amino Acid Recovered Radioactivity in 18 % Incorporation in 18 
[U-14C]histidine (5.5x106 dpm) 1460 dpm 0.026 
[U-14C]arginine (5.5x106 dpm) Background ----- 
[C5-14C]ornithine (5.5x106 dpm) 1300 dpm 0.024 
[U-14C]proline (5.5x106 dpm) 1180 dpm 0.022 
control background ----- 
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 Based on the radioactivity experiment is that both proline and histidine are 
presented as the most likely natural precursors for stevensine 18 and possibly other 
pyrrole-imidazole derived alkaloids (Figure 9). 
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Figure 9.  Biogenetic precursors of stevensine (18) from the sponge T. morchella. 
 
C.  Synthetic Studies 
 In the last few years, an increasing interest in the pyrrole-imidazole alkaloid 
family has triggered a surge in efforts toward the synthesis of these fascinating 
secondary metabolites.  This is thought to be due to their widespread appearance in 
nature and their general biological activity (specific cellular targets for many of these 
molecules remain unknown), combined with their exquisite structures. 
 
 1.  Biomimetic Approaches 
 The biomimetic synthesis of natural products requires highly selective reaction 
conditions that would trigger the desired mode of oxidation/cyclization, in the case of 
linear substrates like oroidin (1).  Pioneering work in the area of pyrrole-imidazole 
alkaloids was reported by Foley and Büchi in 1982 where an elegant biomimetic 
17 
synthesis of (±)-dibromophakellin (19) was completed.26  The key step in Büchi’s loom 
is the oxidative bromination/cyclization of dihydro-oroidin (20) to the spiro-imidazolium 
intermediate 21 which upon treatment with potassium tert-butoxide in tert-butanol 
produced racemic dibromophakellin (19). 
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 Two decades later, in 2002, Horne and co-workers published the first racemic 
synthesis of (±)-dibromophakellstatin (22) and dibromoisophakellin 
/dibromocantharelline using a biomimetic oxidative cyclization protocol that sets the 
stage for construction of the tetracyclic framework.27  In their approach towards 
dibromophakellstatin 21 they recognized aminoprolyl imidazolone 24 as a potential 
forerunner (Scheme 4).  Imidazole 24 was readily prepared from ornithine methyl ester 
(23) via Akabori reduction and condensation with cyanate.  After considerable 
experimentation, they found that oxidation of imidazolidinone 25 with NBS followed by 
18 
concentration and addition of triethylamine/THF produced racemic dibromophakellstatin 
(22). 
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 Next, in their attempts to synthesize dibromoisophakellin (rac-6) from dihydro-
oroidin (20), Horne and co-workers discovered that their conditions previously used for 
racemic dibromophakellstatin 22 gave excellent yields of racemic dibromophakellin 19 
(Scheme 5).27  This represents a noteworthy improvement over the original Büchi 
conditions.  Treatment of dibromophakellin 19 with K2CO3 in chlorobenzene at 130° C 
caused the N to C rearrangement to deliver dibromoisophakellin/dibromocantharelline 
along with recovered starting material.  This rearrangement represents the first 
successful segway to the isophakellin series. 
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 2.  Synthetic Approaches to the Dipyrrolopyrazinone Core of the Phakellins 
and Phakellstatins 
 Towards the C11N5 metabolites, Lindel and co-workers showed that the relative 
stereochemistry of the carbinolamine formed on the dipyrrolopyrazinone core of the 
phakellins and phakellstatins (meaning the ABC ring system) depends on the 
bromination pattern of the pyrrole moiety.28  Oxidation of the peptide coupling products 
of L-prolinol and pyrrole acid afforded exclusively N,O-hemiacetals 26 and 27 (Scheme 
6).  They found that the presence of a bromine substituent at C5 of the resulting tricycle 
exclusively favors the β-hydroxy tricycle 27, possessing an anti relative configuration of 
the hydroxy group and the adjacent methine hydrogen.  A possible rationale was 
proposed for this observation which is that the hydroxyl group adopts the axial position 
due to an anomeric effect induced by the pyrrole nitrogen when the pyrrole is not 
substituted.  In the dibrominated derivative, the pyrrole moiety is electron poor thus the 
pyrrole nitrogen lone pair does not induce such a strong anomeric effect and the 
hydroxyl group occupies the more thermodynamically stable equatorial position on 
steric grounds.  Interestingly, when diol 29 was exposed to mild acidic conditions only 
20 
one diastereomer was formed, methanol adduct 30.  This proves that the quaternary 
hemi-ketal C10 is stereochemically less stable than its tertiary hemi-acetal homolog C6 
due to the ease of N-acyliminium formation. 
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 Regioselective intramolecular cyclization studies on pyrrole-proline derivatives 
to deliver the ABC tricyclic core of the phakellins/phakellstatins and the isophakellins, 
for example, dibromoisophakellin (6) and ugibohlin (9), have been reported by Al-
Mourabit and co-workers.29  According to the authors, pyrrole N1-C and C3-C 
regioselective cyclization is closely dependent on the electrophilic function, bromination 
degree of the pyrrole moiety and pH conditions.  After some exploratory attempts, 
intramolecular cyclization of Weinreb amide 31 was observed when treated with LiAlH4 
at 0° C (Scheme 7).  Notably, the reaction led to pH dependent cyclization products; 
when the reaction was quenched with 1N HCl, the C3-C cyclization product 32 along 
with enamine 33 was isolated.  On the other hand, when the reaction was quenched with 
21 
just water only N,O-hemiacetal 26 was obtained.  Al-Mourabit and co-workers 
rationalized the formation of 32 as being derived from the corresponding aldehyde after 
complete reduction and hydrolysis of the Weinreb complex.   
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 The authors confirmed that the reduction/cyclization of Weinreb amide 31 is 
totally masked by electronic effects of the bromine atoms since treatment of the 
dibromopyrrole derivative of Weinreb amide 31 under the reaction conditions above 
(reduction and hydrolysis with both 1N HCl and water) gave exclusively N,O-hemiacetal 
27. 
 
 3.  Stereoselective Approach 
 The synthetic challenge presented by the monomeric polycyclic orodin 
derivatives lies on the assembly of heteroatom rich molecules and the construction of 
stereocenters that have proven to be chemically unstable such as carbinolamines and 
22 
aminals.  Poullennec and Romo took that challenge and were the first to report an 
enantioselective total synthesis of (+)-dibromophakellstatin (35), the antipode of the 
natural product 3a.30  As previously mentioned in Section A, this tetracyclic alkaloid not 
only possess exquisite structural features due to its compact size and corresponding 
dense polar functionality but also has interesting biological activity.  They targeted the 
enantioselective synthesis of this alkaloid to enable biological investigations including 
mode of action studies.  Moreover, the group’s interest in the related natural product 
palau’amine (4a) provided further impetus for developing routes to access these unique 
tetracycles as they could reveal potential annulation strategies for the phakellin (2c) 
substructure embedded within palau’amine.  Their strategy was premised on the 
observation that a prolyl-proline anhydride cyclo(Pro-Pro) was embedded within the 
structure of the natural product (Scheme 8).  Hence this core may be accessed via 
desymmetrization of a C2-symmetric diketopiperazine (DKP).  Poullennec and Romo’s 
approach began with (S,S)-cyclo(Pro-Pro) 36 obtained in three steps by a modified 
procedure from L-proline.  Subsequent desymmetrization of the cyclo(Pro-Pro) via 
diastereoselective acylation, followed by dehydrogenation, then reduction and 
esterification which upon hydrogenolysis and treatment with Shioiri’s reagent led to the 
formation of urea 37.  Aminolysis of urea 37 and subsequent epimerization delivered 
trans-carbinolamine 38 which failed to effect the desired cyclization when treated under 
a number of different conditions.  The lability of C10 is presumably due to acyliminium 
chemistry.  The instability of quaternary aminal centers compared to carbinolamines had 
previously been observed by Lindel on his work with dipyrrolopyrazinones.28 
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 Another strategy was taken to complete the synthesis of dibromophakellstatin 35 
in which the C6 more stable aminal had to be introduced first followed by the more 
labile C10 aminal.  β-amino amide 40 possess the desired properties and thankfully 
underwent the tandem Hoffman rearrangement/cyclization followed by hydrogenolysis 
to deliver (+)-phakellstatin, which upon bromination conditions with NBS delivered (+)-
dibromophakellstatin (35) in 16 steps and 1.6% overall yield (Scheme 9). 
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 4.  Racemic Approaches 
 In the last several years, a heave in publications regarding synthetic approaches 
toward the phakellstatins seems to signal a renewed interest in this class of marine 
alkaloids.  Austin and co-workers took advantage of a key syn-diazide formation to 
construct both diamino acetal and diamino ketal centers onto the ABC core structure of 
24 
dibromophakellstatin.31  Their approach utilizes a hypervalent iodine-mediated 
diazidation to assemble a diamine appropriate for the installation of the urea moiety on 
the dihydropyrrolopyrazinone (34) core structure of the natural product (Scheme 10). 
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 Feldman and Skoumbourdis based their synthetic approach in mimicry the 
biosynthetic proposal of many polycyclic marine alkaloids where the oxidation of 2-
aminoimidazole systems with concomitant cyclization of a tethered nucleophile leads to 
formation of their molecular framework.32  Seminal work in this area by Büchi26 and 
Horne27 illustrate the value of this strategy for rapid access to variety of targets like 
dibromophakellstatin (3a) and dibromophakellin (2a).  The authors utilized a variant of 
the Pummerer reaction to carry out a diastereoselective oxidative cyclization of a 
dihydrooroidin derivative (41).  The thioimidate (42) product formed by reaction with 
25 
Stang’s reagent, PhI(CN)OTf, served as a precursor to (±)-dibromophakellstatin 
(Scheme 11). 
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 Within a couple of months after Feldman’s account, Lindel and co-workers also 
reported a racemic synthesis of dibromophakellstatin.33  Lindel’s strategy possess as key 
steps the direct assembly of imidazoline ring (cyclic urea) from the readily available 
unsymmetrical enamide 28 by means of nitrene chemistry and the simultaneous 
deprotection of the nitrogen atoms of the tetracycle 43 with samarium iodide (Scheme 
12). 
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D.  Biological Studies 
 A precedent was set by Scheuer’s12 article in 1998, in which the question of 
whether Sharma’s unidentified potent antibacterial activity might simply have been due 
to phakellin (2c).  This hypothesis was premised by analogy to the findings regarding the 
brominated palau’amines being less active/potent than the non-brominated congener.  If 
the hypothesis is true, and the phakellin substructure of palau’amine is necessary and 
possibly sufficient for its antimicrobial activity, this grants justification to attempt to 
synthesize phakellin.  Harran and Nakadia motivated by this assertion decided to 
synthesize racemic phakellin (±-2c) and test its biological activity.34  They used Horne’s 
modifications27 of Büchi’s protocol to yield (±)-dibromophakellin (±-2a).  Sharma’s 
hydrogenolysis procedure was then employed to generate (±)-phakellin.  When both 
compounds were screened against a variety of gram negative and gram positive bacteria, 
27 
as well as several drug efflux pump mutant strains, they were found to be devoid of 
activity.  The authors claim that phakellin is not Sharma’s missing active compound 
based on the assumption that one enantiomer does not antagonize the action of the other 
while being assayed together. 
 
E.  Conclusion 
 The pyrrole-imidazole alkaloid family of natural products illustrates the diversity 
of topographically unique molecules with potent biological activities that can be found 
in the marine environment.  Not surprisingly, they have attracted a considerable amount 
of interest from the scientific community and are still the subject of intensive on-going 
research. 
 
28 
CHAPTER II 
 
SYNTHESIS OF (-)-DIBROMOPHAKELLSTATIN:  
 
ORIGINAL STRATEGY REVISITED 
 
 
  
 The molecular complexity of the phakellins and phakellstatins poses a 
considerable synthetic challenge considering their compact, heteroatom dense tetracyclic 
core that includes a pyrrole, either a cyclic guanidine or a cyclic urea, and two vicinal, 
stereogenic aminal centers.  These characteristics along with reported biological 
activities captured our attention and we targeted the asymmetric synthesis of these 
marine alkaloids.  In addition, phakellin (2c) is a substructure within palau’amine (4a), 
which provides further impetus for the development of strategies to access this unique 
tetracycle in an efficient and concise manner since it could serve as a model study for 
phakellin annulation in the final stages of our proposed synthesis of palau’amine. 
 In our first asymmetric strategy toward these natural products, it was recognized 
that a bis-proline diketopiperazine (DKP) was embedded within their structure and thus 
a desymmetrization process of a C2-symmetric DKP was utilized to construct these 
molecules.  The first total synthesis of (+)-dibromophakellstatin (35), the unnatural 
enantiomer, which was reported by our group in 2003, proceeded through a potential, 
but not yet isolated, natural product (+)-phakellstatin.30  The synthesis was 16 linear 
steps (from L-proline) and 1.6% overall and thus there is opportunity for optimization 
and improvement.  As mentioned above, phakellin (2c) is embedded within the structure 
of palau’amine, therefore a new more concise strategy for its total synthesis will not only 
29 
improve the current strategy developed in our group for the total synthesis of (+)-
dibromophakellstatin, but it will also provide a succinct annulation approach for the total 
synthesis of palau’amine (Scheme 12). 
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A.  Improving Efficiency 
 Towards improving our first total synthesis strategy toward these alkaloids and 
derivatives, we decided to streamline the linear sequence for the total synthesis of (+)-
dibromophakellstatin (35).  The new approach involved the use of carbomethoxy DKP-
46, easily obtained by desymmetrization of the (-)-bis-proline DKP 44.  By using 46 as 
starting point it would take five steps to reach carbinolamine 47, while the original 
sequence took nine steps to obtain the same intermediate 47 (Scheme 13). 
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 Carbinolamine 47 was an ideal intermediate to intercept in the synthesis since 
from this point the route could diverge to reach two goals.  The first goal entailed 
following the original sequence to prepared monobrominated phakellstatin (48) (Figure 
10).  This mono-bromo derivative would be useful for mechanism of action studies (see 
Chapter III) by palladium (Pd) catalyzed couplings to provide cellular probes.  The 
second goal would follow a similar sequence to access the isolation and characterization 
of an interesting by product, which was isolated by Dr. K. Poullennec and tentatively 
assigned as the C6-hydroxy phakellstatin 49.  Interestingly, the latter compound is 
structurally related to dibromoagelaspongine,35 a natural product that contains a highly 
uncommon ortho-imidine moiety. 
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Figure 10.  Structures of bromophakellstatin 48, an interesting by-product 49, and a 
structurally related natural product, dibromoagelaspongine. 
 
 1.  Attempted Carboxylate Formation 
 Preparation of the C2-symmetric (-)-cyclo(Pro,Pro) DKP-44 was accomplished 
following Yamamoto’s procedure.36  Desymmetrization of the DKP under conditions 
developed in our laboratory for these purposes37 gave carbomethoxy DKP-46 (Scheme 
14).  Dehydrogenation of the pyrrolidine to the pyrroline was accomplished following a 
selenation/oxidation/elimination sequence in good overall yield, even on multi-gram 
scale reactions.  Final dehydrogenation of the pyrroline to provide the functionalized 
pyrrole 50 was efficiently obtained by means of selenium dioxide. 
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 The reduction of the acyl pyrrole carbonyl in 50 with sodium borohydride at low 
temperature yielded the undesired syn carbinolamine 51 (Scheme 15). 
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 The stereochemical outcome of the reaction was realized only later when 
studying conversion to the carboxylate 54.  The idea for the carboxylate formation was 
based on that once this one was formed we could couple it with carbobenzyloxy 
hydroxylamine (CbzNHOH) by means of PyBrop and obtain hydroxamic ester 47 in 
four steps less than the original methodology (Scheme 16). 
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 Numerous conditions were tried in order to obtain carboxylate 54 but all failed 
(Table 3).  Krapcho conditions were studied first using lithium iodide in an aprotic polar 
solvent, THF.5  Theoretically, in the system there is a “pulling factor” via coordination 
with the lithium ion and a “pushing factor” from the nucleophile iodide ion both of 
which contribute to the carbon-oxygen bond cleavage.  It is also important that the 
solvent possess a dielectric constant < 10.5a  For this purposes the preferred solvents are 
ethyl acetate (ε = 6.0) and tetrahydrofuran (ε = 7.6); however, other solvents can be 
employed, for example, dichloromethane (ε = 8.9).  It is proposed that the ability of the 
lithium ion to activate the carbonyl is lost if the solvent’s dielectric constant > 10. 
 
Table 3.  Attempted carboxylate formation of 51. 
N
N
O
HO
MeO
O
M N
N
O
HO
O
O
51
N
N
O N
N
O
HO
MeO
O
533454
 
Entry Conditions Outcome 
1 LiI, THF, reflux Decarboxylation (34) 
2 LiI, THF, 22  50° C epimerized + unidentified 
3 LiI, EtOAc, 22  50° C epimerized + unidentified 
4 LiI, CH2Cl2, 22  reflux epimerized + unidentified 
5 LiOH, THF/H2O, 22° C epimerized + unidentified 
6 LiI, THF, MeOH(cat.), 22  50° C epimerized + unidentified 
7 LiCl, DMF, 22° C Multiple spots 
8 KCN, DMF, 22° C Multiple spots 
9 KSCN, DMF, 22° C Multiple spots 
10 Amberlite, THF, 22° C One spot (53) 
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 The product of entry 1 was identified as enamide 34 by direct comparison with 
published data for this compound (1H NMR).39  From that result we inferred that 
carbinolamine 51 might not be very stable to high temperature conditions.  Changes in 
solvent and/or temperature and time of reaction did not prove beneficial (Entry 2-4, 6).  
Changes in the hardness of the nucleophile, iodide to chloride, or changing the cation for 
a soft ion like potassium and having soft nucleophiles like cyanide or thiocyanate, had 
no effect on the reaction outcome.  Unexpectedly, amberlite gave a clean spot to spot 
reaction (Entry 10).  The product of the reaction was identified as the diastereomer (α-
hydroxy-53) of the starting material, epimerization of the alcohol had occurred under 
these reaction conditions. 
 
 2.  Attempted Transesterification 
 Since demethylation proved more difficult than expected, we proposed an 
alternate route.  A direct transesterification of hydroxy methyl ester 53 with N-
hydroxycarbamate (CbzNHOH) using Otera’s catalyst40 which would remove the need 
for a protection/deprotection sequence used in our original strategy was sought.  This 
strategy would deliver the Mitsunobu precursor 47 in four steps less than the original 
methodology.  After various trials, varying time, equivalents of reagents, and catalyst 
loading, we finally were able to isolate one major product out of the reaction mixture, 
benzylester 55 (Table 4).  We verified its identity by comparison with a known sample 
previously prepared by Dr. K. Poullennec.39  Although the results compelled us, they 
were not totally surprising considering the fact that CbzNHOH is just a protected form 
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of benzyl alcohol.  Classical transesterification conditions require that the alcohol 
partner be in excess relative to the ester.  However, it appears that the propensity of the 
masked alcohol to undergo Lossen rearrangement leading to benzyl alcohol which then 
reacts under the reaction conditions to provide benzyl ester 55 is surprisingly faster than 
transesterification with the α-nucleophile, CbzNHOH. 
 
Table 4.  Attempted transesterification of hydroxy methylester 53 with CbzNHOH. 
N
N
O
HO
MeO
O N
N OCbzHNO
O
HO
4753
N
N
O
HO
BnO
O
55
Sn
HO Sn
O
O
Sn
Sn
OH
Cl
Cl
Bu
Bu BuBu
Bu Bu
Bu
Bu
Otera's Catalyst
 
Entry Conditions Outcome 
1 CbzNHOH, Otera’s cat., Tol., reflux Complex mixture 
2 CbzNHOH, Ti(O-iPr)4, DME,  100° C No Rxn 
3 CbzNHOH, I2, Tol., reflux No Rxn 
4 CbzNHOH, Otera’s cat., Tol., reflux Benzyl ester (55) 
                          
 
 We also tried the transesterification conditions with the syn diastereomer 51, but 
no desired product was obtained, instead epimerization of the C6 center or no reaction 
was observed. 
 
B.  Revisiting the Original Strategy 
 Our approach to improve the current methodology encountered several 
unanticipated problems.  Therefore, it was decided to take advantage of the strategy 
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previously devised in our laboratories for the total synthesis of (+)-dibromophakellstatin 
and utilize this for the synthesis of the naturally occurring enantiomer (-)-
dibromophakellstatin.  Employing the original strategy, we wanted to prepare ample 
quantities of the compounds of interest (vide supra) bromophakellstatin, C6-hydroxy 
phakellstatin along with dibromophakellstatin and phakellstatin for mode of action 
studies.  In order for us to prepare enough material of the desired compounds, we started 
with bulk amounts of D-proline.  We were able to prepare 68.8 g of the C2-symmetric (-
)-cyclo(Pro,Pro) DKP-44.  Desymmetrization of the DKP under conditions developed in 
our laboratories for these purposes gave us 84.6 g of the Cbz-DKP 45 (Scheme 17). 
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 We proceeded with the synthetic sequence to reach carbinolamine 47.  This was 
an important intermediate since it would diverge to two synthetic pathways which lead 
to different compounds of interest (Figure 10, vide supra). 
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 With the carbinolamine 47 in hand, we submitted it to the next set of known 
conditions which entail a three step/one pot reaction to form the β-amino amide 59.  This 
process invokes an intramolecular delivery of the nitrogen to the C6-position by means 
of the hydroxamate via Mitsunobu conditions (DIAD, PPh3) in refluxing THF, followed 
by aminolysis, and cleavage of the N-O bond with titanium trichloride.  However, 
several attempts to reproduce these results were unsuccessful for obtaining the desired β-
amine amide 59. 
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 Careful analysis of the reaction conditions and varying reaction times, 
temperature, and order of addition of reagents did not lead to positive results.  Currently, 
we do no have a concrete explanation for why this three step/one pot sequence did not 
work in our hands.  If the reaction had proceeded to deliver β-amino amide 59 the next 
step was to submit it to Hofmann rearrangement conditions, namely [bis-
(trifluoroacetoxy)]iodobenzene (BTI) in pyridine and acetonitrile, followed by 
hydrogenolysis of the Cbz group to afford (-)-phakellstatin.39 
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C.  Future Studies 
 As mentioned before, the material obtained up to the carbinolamine stage would 
be divided and the sequence would bifurcate to two synthetic pathways.  The first one 
will follow the original method toward completion of the synthesis of (-)-
dibromophakellstatin, the naturally occurring enantiomer (Scheme 19).  We also plan to 
study the monobromination of (-)-phakellstatin.  Preliminary studies in our laboratories 
showed promising results although the regioselectivity of the bromination was never 
confirmed.5  Even though bromophakellstatin has never been isolated from nature, it is 
likely to be present as related marine natural products containing monobrominated 
pyrroles are known, as in the case of the phakellins and palau’amines.  Alternatively, if 
the monobromination fails, a selective reduction by means of SmI2 could be utilized as 
has been previously shown by Lindel.33 
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 The second pathway will enable further study of the potentially interesting by-
product isolated by Dr. K. Poullennec and tentatively assigned as C6-hydroxy 
phakellstatin (49).5  The latter was found after attempts to introduce the first nitrogen of 
the urea moiety into the C6 aminal center via the Mitsunobu protocol which led to the β-
amino amide 60 (Scheme 20).  To unmask the β-amine functionality, the benzyloxy 
carbonyl group was removed by hydrogenolysis.  The free hydroxyl amine was 
subsequently acetylated to give N-acetoxy amine 61.  Exposure of 61 to BTI afforded a 
polar product which was tentatively as 49. 
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 The proposed mechanism for this transformation begins with loss of acetic acid 
via E2 elimination caused by pyridine.  Direct oxidation of the β-imino amide 62 can 
lead to a Hofmann-type rearrangement mediated by the hypervalent iodine species and 
isocyanate 64 would be trapped by the pendant amino group of the carbinolamine 
formed by addition of water to the imine moiety (Scheme 21). 
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D.  Conclusion 
 Our attempt to streamline the original methodology to (+)-dibromophakellstatin 
and shorten the synthesis by 5 steps was not fruitful.  This forced us to reconsider the 
original strategy and use it to synthesize (-)-dibromophakellstatin, the natural occurring 
enantiomer.  The sequence was reproducible until we reached carbinolamine 47.  The 
next step, involving the 3 step/one pot sequence proved problematic and in our hands the 
reaction was never successful.  This precluded us from finishing the synthesis of the 
natural enantiomer and additional compounds of interest. 
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CHAPTER III 
 
STUDIES TOWARD (+)-DIBROMOPHAKELLIN AND CONGENERS: 
 
A C-H INSERTION STRATEGY 
 
 
A.  Introduction 
 
 Previous work from our laboratories which culminated in the synthesis of (+)-
dibromophakellstatin provided the first enantioselective approach toward this tetracyclic 
oroidin class of marine metabolites and it could potentially be applied to the late stages 
of palau’amine synthesis.  However, we recognized that a more concise phakellin 
annulation strategy would greatly simplify our strategy toward the highly complex 
alkaloid palau’amine.  The second generation strategy towards phakellstatin and 
phakellin was premised on a C-H insertion process developed by Du Bois and co-
workers.41   
 In our first strategy en route for (+)-dibromophakellstatin, we discovered the 
extreme difference in reactivity/stability of the diamino ketal (C10, phakellstatin 
numbering) in comparison with the pyrrolo aminal (C6) (see Chapter I, Scheme 8).  The 
lability of the quaternary C10 center is likely due to acyliminium chemistry.42  
Concurrent with our studies, the unusual stability of pyrrole carbinolamines was also 
observed by Lindel28 and Evans.43  Based on the finding that the quaternary C10 amino 
ketal center of the natural product must be introduced at a late stage of the synthesis due 
to its instability, the urea/guanidine 65/66 (respectively) was considered a viable 
precursor of (-)-phakellstatin and (-)-phakellin via the Du Bois C-H insertion 
42 
methodology (Scheme 22).  In principle, 65 and/or 66 could be obtained from hemi-
aminal 67 which could in turn arise from cyclization of a transient imine.  Final 
disconnection of the corresponding masked aldehyde leads to the two commercially 
available substrates, 2-pyrrole carboxylic acid (69) and prolinol (70).   
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 Three main advantages are derived from this strategy.  First, it would potentially 
grant access to both natural products in a unified approach from a common intermediate 
(67).  Second, it would reduce the number of steps in the current methodology by more 
than half (from 16 to 7, longest linear sequence).  And lastly, it would expand the scope 
of the C-H insertion process and the array of possible substrates since the number of 
natural products that contain either cyclic ureas and/or guanidines is quite vast and this 
methodology could potentially be used to access some these complex molecules. 
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 1.  C-H Insertion with Metallonitrenes 
 The key step in our second generation approach is a rhodium-catalyzed C-H 
insertion into the tertiary aminal (C10) center of intermediates 65/66.  Seminal work in 
the area by Du Bois inspired us to examine this methodology as a mean to rapidly 
construct the phakellins and phakellstatins. 
 A unique catalytic method for the oxidative cyclization of carbamates to 
oxazolidinones using [Rh2(OAc)4] was described in 2001 by Du Bois and co-workers.  
In this initial account, the authors report that substrates containing both benzylic and 
tertiary C-H centers underwent cyclization to oxazolidinone products in yields ranging 
from 74 – 84% (Scheme 23).41  This reaction is thought to occur through an 
intramolecular metal-nitrene insertion, though little mechanistic data has been offered in 
support of this claim.44  Assertions that direct insertion of a nitrene or nitrenoid 
intermediate into a methine center should occur with retention of configuration have 
been posited previously in the literature,45 for example Meth-Cohn’s work pertaining to 
C-H insertion of nitrenoformates. 
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 Later that same year, Du Bois and co-workers showed that this methodology 
could also be used with sulfamate esters to afford oxathiazinanes.41b  This class of 
compounds produced exclusive γ-C-H bond amination; finding that contrasted 
distinctively with their previous results with carbamates (Scheme 24).  The authors 
proposed that the strong bias for oxathiazinanes formation is presumably accounted for 
by the elongated S-O and the shortened S-N bond (1.58 Å, average length found for both 
bonds) and the obtuse N-S-O angle (103°) of the sulfamate.46  It was also noted by the 
authors that it is possible to efficiently prepare the five-membered sulfamidate in 
systems where no other alternative cyclization pathway is available.  Good yields were 
obtained (60-91%) and preference for the 1,3-syn diastereomers ranged from 4:1 to 
>20:1. 
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 Importantly, this type of C-H insertion had not been reported employing ureas 
and/or guanidines moieties as reacting functionalities until fairly recently.  Rather, 
reports to date by Rojas,47 Padwa,48 Parker,49 and others50 working on the further 
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development of this C-H amination methodology have employed carbamates and 
sulfamates.  However, Du Bois recently and highly pertinent to our strategy, reported the 
use of guanidines and ureas for C-H insertion chemistry (Scheme 25).51  This adds 
further to the versatility of such processes by increasing its application in synthesis 
because of its efficiency, predictable selectivity, and the value of the heterocycles that 
can be produced.  For example, heterocyclic ureas and guanidines are found as structural 
elements in a growing number of complex, biologically efficacious targets, including the 
greatly diverse family of bromopyrrole alkaloids. 
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 The success of these reactions is predicated on the choice of the electron-
withdrawing 2,2,2-trichloroethoxysulfonyl (Tces) protecting group, the commercial 
catalyst Rh2(esp)2 (esp = α,α,α’,α’-tetramethyl-1,3-benzenedipropionate), and toluene 
as solvent.  When compared to trifluoroacetyl, p-tolylsulfonyl, and nosyl, only the Tces 
group led to an effective oxidative cyclization for both moieties.  This group also serves 
as a useful, robust protecting group for the polar urea and guanidine functionalities. 
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 2.  Application to Natural Product Synthesis 
 The Rh-catalyzed C-H insertion methodology is practical and tolerant of many 
different functional groups; therefore it is not surprising that this process has been 
elegantly exploited in natural product synthesis.  In their synthesis of the bromopyrrole 
alkaloids manzacidin A and C in 2002, Wehn and Du Bois used the sulfamate ester-
based nitrenoid C-H insertion to form a pivotal C-N bond in 71 in a stereospecific 
fashion (Scheme 26).52  By employing this chemistry a rapid, enantioselective synthesis 
was achieved.  The synthesis of manzacidins A and C demonstrated for the first time the 
efficacy of Rh-catalyzed sulfamate ester insertion reactions in the context of complex 
natural product synthesis. 
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 The carbamate variant of this chemistry was showcased in the synthesis of the 
potent ion channel blocker, (-)-tetrodotoxin (TTX).53  This metabolite is one of nature’s 
most marvelous compounds.  Its elaborate chemical architecture includes a densely 
oxygenated cyclohexane framework, a unique ortho-acid, and guanidine functionalities.  
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Hinman and Du Bois envisioned in their planning that stereospecific metal-mediated 
carbene and nitrene C-H insertion reactions would hallmark the defining bond 
constructions in their approach to TTX (Scheme 27).  The utility of the C-H amination is 
especially noteworthy given the structural complexity of the substrate. 
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 In 2002, Trost and co-workers published the total synthesis of the novel 
antitumor agent callipeltoside A, and several analogs.54  The northern part of this 
molecule is a sugar derived bicycle named methyl callipeltose.  The authors used the Du 
Bois C-H insertion methodology to make the oxazolidinone moiety of this molecule 
(Scheme 28).  With this approach they were able to simplify the synthesis of callipeltose 
compared to what had been previously reported, leading to the shortest reported 
synthesis of this sugar moiety. 
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 Later, Huang and Panek reported a new approach to an enantioselective synthesis 
of methyl-L-callipeltose.55  The final stage of the synthesis was based on Trost’s results 
for the Rh-catalyzed C-H insertion of the carbamate moiety.  While Trost and co-
workers obtained from 63 to 64% conversion of the C-H insertion product using 10 mol 
% of the Rh catalyst in refluxing CH2Cl2; Panek’s laboratory obtained complete 
conversion using 20 mol % of the catalyst in refluxing CH2Cl2.  Moreover, they were 
able to obtain 93% conversion using 10 mol % of the Rh catalyst in refluxing benzene 
(Scheme 29). 
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 Recently, a stereoselective synthesis of the immunomodulator (+)-conagenin was 
described by Yakura and co-workers.56  The Rh-catalyzed C-H amination reaction was 
utilized as a key step to synthesize the α-methylserine fragment (72) of conagenin 
(Scheme 30). 
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 The successful completion of these syntheses offers testament to the power of C-
H functionalization as a unique strategy for assembling complex targets and further 
validates the Rh-catalyzed nitrene insertion as a powerful new tool in synthesis. 
 
B.  Development of a C-H Insertion Strategy 
 Du Bois and others have reported the application of the oxidative C-H insertion 
reaction with carbamates and sulfamate esters to produce oxazolidinones and 
oxathiazinanes respectively.  However, when our laboratories initiated studies toward 
applying this methodology to the phakellins and phakellstatins, it had not been extended 
to ureas or guanidines.  Thus, we planned to probe the viability of this second generation 
approach utilizing a C-H insertion as a key bond disconnection. 
 
 1.  Model Studies 
 Two model systems were designed to initially investigate the aforementioned 
protocol.  In the first model, cyclohexylamine 73 was readily converted to urea 74 by 
tosylation and consecutive acylation (Scheme 31). 
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 Disappointingly, exposure of urea 74 to Du Bois C-H insertion conditions did not 
succeed in delivering bicyclic imidazolidinone 75.  Not discouraged by this result, we 
next designed a model substrate that would prove more reactive towards C-H insertion, 
namely a molecule with a methine hydrogen adjacent to a heteroatom.  Carbamate 78 
posed itself as a suitable model for the construction of a five-membered oxazolidinone.  
Its synthesis was achieved by acylation of readily available Boc-L-prolinol (76) as 
shown in Scheme 32.  Pleasingly, upon exposure to C-H insertion conditions, carbamate 
78 delivered spiro-oxazolidinone 79, albeit in low yield, along with unreacted material. 
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 2.  Synthesis of the Imine Precursor 
 To attain the naturally occurring enantiomer of phakellstatin, we would have to 
begin the synthesis with D-prolinol (70).  However, we initiated the studies with less 
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expensive L-prolinol.  In the case of dibromophakellin, this is not an important issue 
since both enantiomers are naturally occurring.9a, 14   
 Our initial synthetic strategy toward the C-H insertion substrate is based on the 
cyclization of a latent imine.  N-hydroxy carbamate 82 presented itself as an apposite 
imine precursor.  The synthesis began with Boc-L-prolinol (76) and reaction under 
Mitsunobu conditions with N-acetoxy benzylcarbamate (OAcNHCbz) afforded N-
acetoxy prolinamide 80 in moderate yield (Scheme 33).  Isolation of N-acetoxy 
prolinamide 80 proved to be troublesome with yields ranging from 13 to 54%.  
Following removal of the acetate and Boc protecting groups, the resulting free amine 
was acylated with pyrrole-2-carbonyl chloride (A) to provide N-hydroxy carbamate 82 in 
low yield. 
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 Attempts to improve the N-acylation reaction of N-hydroxy prolinamide 81 
proved to be a difficult task.  After taking a closer look at the reaction, we were able to 
identify why the reaction was low yielding as a mixture of desired N-hydroxy carbamate 
52 
82 and bis-acylated carbamate 83 was obtained under reaction conditions with the latter 
as the major product (Scheme 34).  This was not completely unexpected considering the 
fact that a hydroxyl amine is more nucleophilic than a secondary alkyl amine. 
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 We tried to hydrolyze bis-acylated carbamate 83 to desired N-hydroxy carbamate 
82 by treatment with potassium carbonate in methanol, no desired product was obtained.  
Bis-acylated carbamate 83 proved to be quite robust when exposed to high temperature 
conditions, namely THF/reflux and toluene 110° C, without undergoing decomposition 
or any other alteration as judged by TLC and 1H NMR. 
 Ideally, subsequent treatment of N-hydroxy carbamate 82 to dehydration 
conditions (TFAA/py.,57 ClCO2Me/Et3N,58 TsCl/DMAP,59 or Tf2O/2,6-lutidine60) would 
generate a transient imine, which would cyclize to the enantiomer of hemi-aminal 67 
(Scheme 22, vide supra). 
  
 3.  Alternate Approach to the Imine Precursor 
 Since the Mitsunobu reaction of Boc-L-prolinol 76 with OAcNHCbz did not give 
good yields and was hard to purify, we decided to change the nucleophile counterpart 
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expecting better results.  When N-benzyloxy tosylamine 84 was reacted under 
Mitsunobu conditions with 76 no desired product was obtained (Scheme 35). 
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 Efforts to improve the Mitsunobu reaction and nitrogen acylation steps proved 
challenging so we decided to take an alternate route.  We sought to form the annulation 
precursor (imine precursor) by acylating the proline nitrogen first and then couple this 
fragment with the secondary amine.  Following removal of the Boc protecting group, the 
free amine was treated with a solution of freshly prepared pyrrole-2-carbonyl chloride 
(A).  As noted by TLC, two major spots were identified.  After purification we were able 
to identify these products as N-acylated prolinol 86 and bis-acylated prolinol 87 (Scheme 
36).  Unfortunately, the desired product 86 eluted as an inseparable mixture with pyrrole 
dimer 88.   
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 As another route to couple N-acylated prolinol 86 with the secondary amine, we 
sought to convert the hydroxyl group in 86 to a halogen expecting that a direct SN2 
displacement would be more feasible and less problematic than a Mitsunobu reaction 
(Scheme 37).61  Unfortunately, several attempts to replace the hydroxyl group under 
standard conditions (e.g. CBr4/PPh3 and variants) did not lead to the desired bromide 89. 
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C.  Revised Second Generation Approach 
 Initially it was hoped that the nitrogen at the C6 position would be installed via 
an intramolecular cyclization of the transient imine from N-hydroxy carbamate 82.  Alas, 
all the previous attempts to get to 67 were unproductive.  Then, we envisaged using 
Lindel’s approach for the synthesis of the dipyrrolopyrazinone core of the phakellin-like 
pyrrole-imidazole alkaloids.28  The N,O-hemiacetal 27 presented itself as a viable 
common precursor for both (+)-dibromophakellstatin and (+)-dibromophakellin (Scheme 
38).  The revised second generation approach stems from previous findings; the lability 
of the quaternary aminal center C10 (phakellstatin numbering) requires it to be introduce 
at late stage but the tertiary aminal center C6 is itself stable to various conditions hence 
it could installed from N,O-hemiacetal 27.  In principle, the pendant guanidine (92) 
and/or urea (91) could be obtained from N,O-hemiacetal 27 by means of Mitsunobu 
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reaction/functional group addition (FGA).  Final disconnection of the corresponding 
masked aldehyde leads to dibromopyrrolyl trichloromethylketone 93 and L-prolinol 94. 
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 1.  Preparation of N,O-hemiacetal 
 The preparation of the starting materials L-prolinol62 94 and dibromopyrrolyl 
trichloromethylketone63 93 was done following literature procedures and both were 
obtained in excellent yields (Scheme 39). 
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 Once again, to achieve the natural enantiomer of dibromophakellstatin, we would 
have to begin with D-prolinol (70).  However, we initiated synthetic studies with the less 
expensive L-prolinol (94).  Due to the fact that both enantiomers have been isolated from 
nature, this is not an issue in the case of dibromophakellin. 
 The synthesis of the key N,O-hemiacetal intermediate (27) was achieved by 
peptide coupling of L-prolinol and dibromopyrrolyl trichloromethylketone followed by 
cyclization using IBX/DMSO (Scheme 40).28  The peptide coupling reaction gives bis-
acylated peptide 96, as by product, which can be hydrolyzed under saponification 
conditions to 95 in moderate yield. 
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 2.  Installation of the Hemi-aminal 
 Introduction of the first nitrogen of the cyclic urea and/or guanidine onto the C6 
position of the ABC core structure of the phakellins and phakellstatins was achieved by 
treatment of the N,O-hemiacetal with diphenylphosphoryl azide (DPPA) and DBU 
(Scheme 41).  Attempts to isolate the azide in pure form by silica gel chromatography 
have failed since one of the by-products of the reaction, enamide 28, co-elutes with the 
azide.  The mixture was taken onto the next step.  We expected to be able to separate 
hemi-aminal 98 from the eliminated product after reduction, but when the mixture was 
treated with PPh3/THF/H2O the desired product was obtained along with P(O)Ph3 even 
after purification on silica gel chromatography.  Due to the problem of contamination 
with P(O)Ph3, we decided to find alternative ways to get around this.  We did not want to 
use hydrogenation conditions to reduce the azide because the bromines on the pyrrole 
ring were prone to cleavage under this condition.  A smaller trialkyl phosphine was the 
reagent of choice since the phosphine oxide by-product is volatile and easily removed 
under high vacuum conditions. 
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 3.  N-Activating Group Installation 
 During the initial studies by the Du Bois group while developing carbamate and 
sulfamate ester insertion reactions, they discovered that an electron-withdrawing group 
aids the stability/reactivity of the nitrene intermediate.  The nitrene intermediate is 
believed to be the reactive species that undergoes the oxidative insertion onto the C-H 
bond with the assistance of a rhodium catalyst.  For the N-alkyl-N-sulfonyl ureas, only 
the Tces group proved to be effective for oxidative cyclization.50b 
 Once we obtained the hemi-aminal, the substrate was ready to be protected and 
acylated to form the pendant urea.  The reaction of the hemi-aminal with 
trichloroethoxysulfonyl chloride64 (Tces-Cl) has proven to be problematic.  The main 
problem is the formation of enamide 28 which decreases the yield of the desired product 
(Table 5).  Ranging from 2 to 10 equivalents of Tces-Cl in conjunction with different 
nucleophilic and non-nucleophilic bases and different temperatures yielded unpromising 
results.  The highest yield (18%) was obtained when Tces-Cl and DMAP in pyridine as 
solvent were used (entry 6).  But the reaction produces multiple spots which makes the 
purification difficult. 
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Table 5.  Attempted Tces protecting group installation. 
N
N
O
H2N
H
Br Br
98
N
N
O
HN
H
Br Br
Tces
99
N
N
O
Br Br
28
+
 
Entry Conditions Outcome 
1 Tces-Cl (2 eq), Et3N, DMAP, THF, 22° C 28 + SM 
2 Tces-Cl (2 eq), pyridine (2 eq), CH2Cl2, 22° C 28 + SM 
3 Tces-Cl (2 eq), pyridine (2 eq), THF, -78° C 28 + SM 
4 Tces-Cl (2 eq), pyridine, 0° C  22° C 28 + 99 (16%)a 
5 Tces-Cl (4 eq), pyridine, DIPEA (4 eq), 0° C  22° C 28 + 99 (15%)a 
6 Tces-Cl (10 eq), DMAP (10 eq), pyridine, 0° C  22° C Multiple spots (18%)a 
7 Tces-Cl (10 eq), PPY (10 eq), pyridine, 0° C  22° C Multiple spots (15%)a 
8 Tces-Cl (5 eq), Et3N (5 eq), pyridine, 0°  22° C 28 + SM 
        a
 Isolated yield of the product. 
 
 4.  Acylation of the N-Tces Hemi-aminal 
 Once with the N-Tces protected hemi-aminal in hand we were ready to acylate 
the nitrogen atom so to form the urea moiety.  This difficult process required extensive 
experimentation that ultimately led to unfruitful results (Scheme 42).  Reaction of the 
hemi-aminal under different basic conditions, varying order of addition of 
reagents/substrates and temperature, did not yield the desired product.  Under microwave 
forcing conditions no desired pendant urea was observed.  Reactivity was observed when 
utilizing a different isocyanate, trichloroacetyl isocyanate (TAI), but the reaction mixture 
was complex. 
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Scheme 42 
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a
 Conditions:  Bases like LHMDS, NaH, Cs2CO3; TMSNCO as electrophile; from 0° C to reflux in THF.  
Mostly starting material and some elimination product.  b TMSNCO and TAI were used; DIPEA was 
added as acid scavenger; THF as solvent; temperature 110 – 125° C from 30 min. to 1.5 hrs.  Some 
starting material and decomposition. 
 
 Using similar reaction conditions we tried to install the pendant urea onto a N-
tosyl hemi-aminal using TAI, but a complicated mixture of products was obtained. 
 
 5.  Alternative Approach to Urea Formation 
 Since efforts to install the protected pendant urea onto the tricyclic core of the 
phakellstatins have failed, we decided to work on a model system and investigate the 
reactivity and behavior of these types of systems under variety of reaction conditions.  
We prepared a model that contained a pendant urea attached to a secondary carbon that 
was somewhat reminiscent of the real system.  N-trichloroacetyl-N’-cyclohexylurea 101 
was prepared by reaction of cyclohexylamine with TAI in good yield (80%).  Attempts 
to selectively protect the amidine moiety resulted unfruitful (Table 6).  In all the cases 
the starting material was recovered. 
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Table 6.  Attempted selective tosylation of N-trichloroacetyl-N’-cyclohexylurea 101. 
N
H
N
O
CCl3
O
102
TsH
N
H
N
O
CCl3
O
101
 
Entry Conditions 
1 TsCl, Et3N, CH2Cl2, 22 to 60 °C 
2 TsCl, pyridine, CH2Cl2, 22 to 60 °C 
3 TsCl, DMAP, CH2Cl2, 22 to 60 °C 
4 TsCl, Et3N/DMAP, CH2Cl2, 22 to 60 °C 
5 Ts2O, Et3N/DMAP, CH2Cl2, 22 to 60 °C 
6 KHMDS (2.1 equiv.), THF, TsCl, 22° C 
7 KHMDS (2.1 equiv.), THF, TsCl, 0° C 
8 KHMDS (2.1 equiv.), THF, TsCl, -78° C 
9 KHMDS (2.1 equiv.), THF, Ts2O, 0° C 
10 KHMDS (2.1 equiv.), THF, Ts2O, 22° C 
 
 
 6.  Installation of the Tces-urea Moiety onto the ABC Core of 
Dibromophakellstatin 
 The amidine model system did not serve our purposes as to find ways to install 
the protected pendant urea.  While working on these systems, Du Bois et al. published a 
communication on the preparation of a Tces-protected urea51b and its use as nucleophile 
in Mitsunobu reactions and C-H insertion substrate to construct cyclic ureas.51  With the 
Tces-urea in hand we proceeded to try the Mitsunobu reaction to append the urea moiety 
onto the tricyclic core of the phakellstatins (Scheme 43).  Unfortunately, under several 
reaction conditions varying temperature, time, and the phosphine reagent, either no 
reaction or just starting material alongside with enamide 28 was observed.  It was not 
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surprising to observe the elimination by-product (28) now that, under basic conditions 
like in the Mitsunobu reaction, dehydration of the N,O-hemiacetal would be expected.  
The substrate is set for E2 elimination leading to a more thermodynamically favored 
product.  The difficulty with the Mitsunobu reaction could be due to the electron density 
of the bromine in position C5, which might be interfering with the nucleophile and 
therefore precluding or diminishing the reactivity at the C10 center. 
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 7.  Installation of the Pendant Guanidine Towards Dibromophakellin 
 Connection of the Tces-urea moiety onto the tricyclic core of the phakellstatins 
was not a trivial task, so we decided to step back on it for while and focus on the 
synthesis of dibromophakellin.  Formation of the isothiourea intermediate (104) was 
accomplished following a procedure by Saulnier and co-workers.65  Reaction of the 
hemi-aminal 98 with imidochloride51b 103 proceeded smoothly and in good yield (67%) 
as shown in Scheme 44.  The isothiourea 104 was then successfully converted to the 
corresponding guanidine in excellent yield (94%). 
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 8.  Attempted C-H Insertion 
 Finally, the much awaited C-H insertion substrate was obtained.  Guanidine 105 
was submitted to Du Bois C-H amination conditions; disappointingly, it did not yield the 
desired cyclic guanidine.  After increasing catalyst loading (1 – 10 mol %), reaction 
temperature (40 – 110° C), reaction time (9 – 18 hrs), and changing solvents (toluene to 
dichloromethane), we hypothesized that the catalyst [Rh2(esp)2] might be too bulky to 
actually reach the nitrene intermediate (Scheme 45).  We decided to try a smaller 
dimeric rhodium catalyst that had been used for C-H insertion reaction but with different 
moieties (i.e. carbamates and sulfamate esters), namely [Rh2(OAc)4], but this also did 
not produce the desired product. 
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 9.  Structural Analysis of Aminal and Carbinolamine: C-H Insertion 
Precursors and Substrates 
 These results raised the question of the stereochemistry at the guanidine center.  
We were aware that there may be concerns about regioselectivity of the C-H insertion 
process, the structure of substrate 105 would appear to preclude the formation of a six-
membered cyclic urea as the methylene protons of the pyrrolidine ring are too far away 
for the insertion process.  Furthermore, the desired site of reaction, namely the methine 
hydrogen at C10, is activated by polarization due to the attached amide nitrogen.  Also, 
direct insertion of the nitrene should occur with retention of configuration premised on 
the stereospecificity that has been observed by Du Bois and others.  We decided to 
perform nOe studies on our substrates. 
  a)  nOe Studies 
 Intrigued by the outcome of the C-H insertion reaction, we decided to take a 
closer look at guanidine 105 and corroborate the relative stereochemistry of both C6 and 
C10 centers.  NOESY 1D experiments were performed on the substrate which revealed 
that indeed C6 (guanidine-bearing carbon) was inverted and that the pendant guanidine 
was positioned in the β-face of the molecule in an anti relationship to the methine 
hydrogen at C10 (Figure 11).  These positive nOe enhancements provide strong evidence 
for us to say that the incorrect epimer was obtained. 
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Figure 11.  Diagnostic nOe enhancements observed in the guanidine 105. 
 
  b)  Coupling Constant Analysis 
 To supplement the nOe studies, a coupling constant analysis was conducted to 
support the proposed relative stereochemistry and to verify where in our synthesis the C6 
center epimerized.  Considering the literature coupling constants (J) for N,O-hemiacetal 
26 and 27,28 the one obtained experimentally for azide 97 correlated with 26, meaning 
that inversion of configuration at that center did occurred.  But when we look closely at 
the coupling constant for hemi-aminal 98 is noticeable that it is now 2.5 Hz, clear 
indication that it has epimerized and no longer is the amino functional group in the same 
spatial arrangement as the methine hydrogen at C10; another piece of evidence that 
supports the inverted relative stereochemistry for C6 relative to C10 (Figure 12). 
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Figure 12.  Experimental and literature coupling constants for the intermediates 27, 97, 
and 98. 
 
  c) X-ray Analysis 
 Fortunately, we were able to do crystallographic structure analysis on the 
isothiourea 104 which confirmed what the other pieces of evidence were pointing to that 
the stereochemistry at the C6 position is opposite to what is needed in order for the C-H 
insertion reaction to proceed.  The structure was solved by heavy-atom methods.  The 
ORTEP diagram of one molecule of 104 as viewed along the y axis is shown in Figure 
13.  The coordinates of all atoms found in the electron-density maps, together with their 
estimated standard deviations (except for hydrogens) are listed in Table 8 of the 
Appendix B.   
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Figure 13.  Perspective ORTEP diagram of isothiourea 104.  The thermal vibration 
ellipsoids are shown on a 50% probability scale. 
  
 Crystals suitable for X-ray diffraction were obtained for guanidine 105.  The 
absolute stereochemistry for the two chiral centers of guanidine 105 were assigned 
(using X-ray numbering) as 9S, 10S.  The skeleton of guanidine 105 as revealed by X-
ray analysis is in complete accord with the one proposed on the basis of spectroscopic 
data and chemical studies.  The crystallographic data indicate that the pendant guanidine 
moiety is in the trans-position relative to the hydrogen at C9 (X-ray numbering).  The 
ORTEP diagram of one molecule of 105 as viewed along the y axis is shown in Figure 
14. 
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Figure 14.  Perspective ORTEP diagram of guanidine 105.  The thermal vibration 
ellipsoids are shown on a 50% probability scale. 
 
 10.  Inversion or Retention 
 The question of stereochemistry at the guanidine bearing carbon has been 
answered by X-ray structure analysis.  The query now is to investigate when 
epimerization is occurring.  According to our coupling constant analysis and further 
studies on the formation of azide 97, inversion of configuration at C6 did happen at this 
stage.  After reduction of the azide under variety of conditions, it is clear that 
epimerization is indeed occurring at this point (Table 7). 
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Table 7.  Studies on the reduction reaction of azide 97. 
N
N
O
BrBr
N3
N
N
O
BrBr
H2N
97 107
N
N
O
BrBr
H2N
98
 
Entry Conditions Outcome (107:98) 
1 PMe3, THF, 30 min. 0°C, then H2O, reflux 1 h 98 
2 PMe3, THF, 30 min. 0°C, then H2O, 22° C, 8 h 98 
3 PPh3, THF, 30 min. 22°C, then H2O, 22° C, 8 h 98 
4 H2, Lindar’s catalyst, MeOH N.R. 
5 SnCl2, MeOH 98 
6 SmI2, THF Complex mixture 
 
 We surmise that epimerization occurs at the stage of iminophosphorane 
formation.  A plausible mechanism by which the epimerization is occurring is outlined 
below (Scheme 46).  Alternatively, epimerization could occur following hydrolysis of 
the iminophosphorane by simple ring opening to an imine and reclosure (107  98). 
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 11.  Correction of Stereochemistry 
 We plan to correct the stereochemistry at the C6 center by removal of the 
bromines on the pyrrole ring of the N,O-hemiacetal 27 prior to the installation of the 
hemi-aminal.  As observed previously by Lindel,28 there appears to be an enthalpic 
difference that governs the anomeric equilibrium at the carbinolamine C6 center dictated 
primarily by the C5 substitution.  When this position is brominated, the preferred 
diastereomer possess a β-hydroxy group and when lacking the C5-bromine a product 
mixture is obtained favoring the α-hydroxy diastereomer in a 9:1 ratio.  Cleavage of the 
bromines by hydrogenolysis and subsequent treatment with DPPA/DBU followed by 
PMe3/THF/H2O should afford the correct hemi-aminal (107) as shown in Scheme 47. 
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D.  Proposed End Game:  Completion of the Synthesis 
 Once the stereochemistry problem at C6 is corrected, installation of the 
isothiourea by means of the imidochloride 103 previously used followed by treatment 
with HgCl2/HMDS to deliver the pendant guanidine 108 (Scheme 48).  The primary 
concern for regioselectivity in the C-H insertion process for this substrate would appear 
to involve the aromatic pyrrole hydrogen at C5.  This regioselectivity will need to be 
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determined experimentally, however if this is found to be problematic, the reaction could 
be performed following bromination of the pyrrole, which would preclude this reaction 
pathway. 
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E.  Conclusion 
 We devised an alternative approach to the phakellins and phakellstatins based on 
a Rh-catalyzed C-H amination protocol developed by Du Bois and co-workers.  Initial 
model studies for the pivotal C-H insertion reaction proved promising for this second 
generation strategy.  Though our early second generation approach to construct aminal 
67 via transient imine 68 resulted on a dead end, we were able to take advantage of 
Lindel’s procedure to synthesize the dipyrrolopyrazinone core (ABC ring system) of the 
phakellins and phakellstatins.  Further functionalization of the N,O-hemiacetal (27) led 
to the formation of the crucial pendant guanidine 105 for the synthesis of (+)-
dibromophakellin, unfortunately this key substrate resulted to be incorrect diastereomer 
which prohibited us to study the crucial C-H insertion reaction.  Ultimately, a similar 
synthetic approach could be applied to the urea containing alkaloid, 
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dibromophakellstatin.  Importantly, this new expedient approach could be directly 
applicable to the projected synthesis of palau’amine. 
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CHAPTER IV 
 
CONCLUSION 
 
 
 
 In summary, our approach to streamline the strategy developed in our 
laboratories for the synthesis of (+)-dibromophakellstatin proved to be quite a challenge.  
Consequently, our ability to reproduce the original approach towards this marine 
alkaloid was hampered by a problematic Mitsunobu reaction which precluded us from 
finishing the synthesis of natural enantiomer (3a) and additional compounds of interest 
(see Figure 10). 
 On the other hand, our second generation approach shows promise as an efficient 
route to the phakellins and it has potential to be applicable to the phakellstatins.  We 
designed a method that allows us to reach the key C-H insertion precursor in 6 steps 
(longest linear sequence) from commercially available prolinol (D or L).  However, the 
current route provides the undesired anti diastereomer for the key pendant guanidine, 
which precluded the study of the pivotal C-H insertion process.  This approach, if 
perfected, would grant access to the targeted alkaloids via the C-H amination of a urea 
and/or of a guanidine to introduce the essential quaternary aminal center.  This would be 
a more amenable approach to the annulation of the phakellin substructure in the final 
stages of palau’amine synthesis.  Furthermore, this methodology could potentially be 
applied to the synthesis of other complex oroidin-derived marine alkaloids. 
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CHAPTER V 
 
EXPERIMENTAL PROCEDURES 
 
 
General 
 All non-aqueous reactions were carried out under a nitrogen atmosphere in oven-
dried (130° C) glassware unless noted otherwise.  Tetrahydrofuran (THF), diethyl ether 
(Et2O), methylene chloride (CH2Cl2), acetonitrile (CH3CN), dimethylformamide (DMF), 
and toluene (PhMe) were dried and purified by a MBRAUN solvent purification system 
by passage under 8 psi N2 through activated molecular sieves.  Methanol (MeOH) was 
distilled from magnesium prior to use.  Dimethylsulfoxide (DMSO, 99.7% AcroSeal) 
was purchased from Acros and used as received.  Pyridine (py) was purchased from EM 
Science and stored under potassium hydroxide (KOH).  Triethylamine (Et3N), 
diisopropylamine, and diisopropylethylamine (DIPEA) were distilled from calcium 
hydride prior to use.  Dimethyldioxirane (DMDO)68 in acetone, phenylselenyl bromide, 
and 2-iodoxybenzoic acid (IBX)69 were prepared following literature protocols.  All 
other commercially available reagents were used as received.  Brine refers to a saturated 
solution of sodium chloride.  Reactions were followed by thin layer chromatography 
(TLC) on SiliCycle® silica gel 60 Å F254 (250 m).  Visualization of the developed plate 
was accomplished by fluorescence quenching and by staining with ethanolic 
anisaldehyde, aqueous potassium permanganate (KMnO4), ceric ammonium molybdate 
(CAM), or vanillin.  Chromatographic purification of compounds was accomplished by 
flash chromatography on SiliCycle® SiliaFlash® F60, 40-63 m 60 Å.   
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 Nuclear magnetic resonance (NMR) spectra were acquired on a Varian Inova-
500 MHz or Inova-300 MHz operating at 500 and 125 MHz, and 300 and 75 MHz for 
1H and 13C, respectively, and are referenced internally according to residual solvent 
signals.  1H NMR coupling constants (J) are reported in Hertz (Hz) and multiplicity is 
abbreviated as follows: app = apparent, s = singlet, d = doublet, dd = doublet of 
doublets, dt = doublet of triplets, t = triplet, q = quartet, p = pentet, m = multiplet, br = 
broad signal.  IR spectra were acquired using a Bruker Tensor 27 FTIR 
spectrophotometer.  Vibration frequencies are expressed in cm-1.  Mass spectra were 
obtained on a MDS Sciex (Concord, Ontario, Canada) API Qstar Pulsar (for ESI) or a 
ThermoFinnigan (San Jose, California) LCQ Deca Mass Spectrometer (for APCI) at the 
Laboratory for Biological Mass Spectrometry (LBMS) at Texas A&M University.   
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N-Acetoxy prolinamide 80.  A solution of Boc-L-prolinol (534.4 mg, 2.655 mmol) and 
triphenylphosphine (767.2 mg, 2.920 mmol) in THF (10 mL) was treated with DIAD 
(575.0 L, 2.920 mmol), followed by CbzNHOAc (666.1 mg, 3.186 mmol).  After 30 
minutes at 23° C, the volatiles were removed under reduced pressure and the residue was 
purified by flash column chromatography (SiO2, hexanes/EtOAc, 9:1) to provide N-
acetoxy prolinamide 80 (564.2 mg, 54%) as a colorless oil:  Rf 0.13 (hexanes/EtOAc, 
9:1); 1H NMR (300 MHz, CDCl3)  7.33-7.40 (m, 5H), 5.18 (s, 2H), 3.88-4.05 (m, 1H), 
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3.69-3.83 (m, 2H), 3.28-3.40 (m, 2H), 2.14 (s, 3H), 1.76-1.98 (m 4H), 1.45 (s, 9H); 13C 
NMR (125 MHz, CDCl3)  169.5, 156.3, 135.0, 128.5, 128.3, 128.2, 127.8, 68.16, 55.10, 
52.15, 51.42, 46.25, 29.61, 29.30, 22.57, 18.21; IR (CDCl3) 1797, 1729, 1694; HRMS 
(ESI) calculated for C20H28N2O6 [M+Na] 415.1845.  Found 415.1827. 
 
N
N
Boc
OAc
Cbz
80
N
N
Boc
OH
Cbz
81
 
N-hydroxy prolinamide 81.  Ammonia (gas) was bubbled into a solution of N-acetoxy 
carbamate (564.0 mg, 1.438 mmol) in MeOH (6 mL) at 0° C for 2 minutes.  After 
stirring the mixture for 15 minutes at 0° C, the volatiles were removed under reduced 
pressure and the residue was purified by flash chromatography (SiO2, hexanes/EtOAc, 
4:1) to provide N-hydroxy prolinamide 81 (428.9 mg, 85%) as a colorless oil; Rf 0.69 
(hexanes/EtOAc, 1:1); 1H NMR (300 MHz, CDCl3)  9.04 (s, 1H), 7.25-7.33 (m, 5H), 
5.20-5.02 (AB, J = 12.0, 41.7 Hz, 2H), 4.20-4.26 (m, 1H), 3.80 (app t, J = 24.0 Hz, 1H), 
3.15-3.26 (m, 3H), 1.88-1.94 (br m, 3H), 1.56-1.60 (m, 1H), 1.39 (s, 9H); 13C NMR (125 
MHz, CDCl3)  169.6, 156.3, 134.9, 128.4, 128.3, 127.9, 68.25, 67.26, 53.18, 46.38, 
28.36, 23.29, 20.89, 18.26; IR (CDCl3) 3232, 2976, 1737, 1690, 1399; LRMS (APCI) 
calculated for C18H26N2O5 [M+H] 351.1.  Found 351.1. 
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N-hydroxy carbamate 82.  To a solution of N-hydroxy prolinamide (100.0 mg, 0.2855 
mmol) in CH2Cl2 (25 ml) was added trifluoroacetic acid (TFA) (198.2 L, 2.569 mmol).  
After stirring at 22° C for 22 h, the volatiles were removed in vacuo.  A freshly prepared 
solution of pyrrole-2-carbonyl chloride (A) was added via cannula to a solution of free 
amine and DMAP (175.0 mg, 1.432 mmol) in CH2Cl2 (25 mL).  After stirring at 22° C 
for 7.5 h, the volatiles were removed under reduced pressure and the residue was 
purified by flash chromatography (SiO2, hexanes/EtOAc, 7:3) to provide N-hydroxy 
carbamate 82 (12.7 mg, 13%) as a yellowish oil:  Rf 0.55 (hexanes/EtOAc, 1:1); 1H 
NMR (300 MHz, CDCl3)  9.48 (s, 1H), 9.39 (s, 1H), 7.20 (br s, 3H) 6.96 (app s, 1H), 
6.64 (app s, 1H) 6.31 (app t, J = 5.4 Hz, 1H) 4.93-5.02 (AB, J = 12.3, 14.1 Hz, 2H), 4.81 
(m, 1H), 3.96 (app t, J = 14.1 Hz, 1H), 3.76 (br s, 2H), 3.31-3.37 (dd, J = 3.9, 14.1 Hz, 
1H), 2.14 (m, 2H), 2.01 (m, 2H) ; LRMS (ESI) calculated for C18H21N3O4 [M+H] 344.1.  
Found 344.1. 
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Bis-acylated compound 83.  Rf 0.32 (hexanes/EtOAc, 1:1); 1H NMR (300 MHz, 
CDCl3)  9.81 (br, 1H), 9.63 (br, 1H), 7.29 (s, 5H), 6.97-6.86 (m, 3H), 6.57 (br, 1H), 
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6.21 (br, 2H), 5.17 (s, 2H), 4.64 (br, 1H), 4.04-4.02 (m, 2H), 3.79 (br, 2H), 2.12-1.94 
(m, 4H); 13C NMR (75 MHz, CDCl3) δ 160.94, 158.61, 155.95, 135.55, 128.41, 128.10, 
127.73, 125.47, 124.88, 121.57, 118.62, 117.68, 112.73, 110.69, 109.81, 68.20, 56.42, 
51.34, 48.61, 27.37, 24.42; IR (CDCl3) 3339, 3252, 1716, 1583, 1440; LRMS (APCI) 
calculated for C23H24N4O5 [M+Na] 459.1.  Found 459.1. 
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N,O-hemiacetal 27.  IBX (333.3 mg, 1.189 mmol) was suspended in DMSO (2.0 mL).  
After 25 minutes of stirring at 22° C the solution became homogeneous and N-acyl 
prolinol was added (209.4 mg, 0.5948 mmol).  The mixture was stirred for 14 h at 22° C.  
The solution was then diluted with 25 mL of water.  The precipitate was filtered off, then 
washed three times with CH2Cl2 (3 x 30 mL).  The organic layers were combined, dried 
under MgSO4, and filtered.  Removal of volatiles in vacuo gave N,O-hemiacetal 27 as a 
white solid (170.1 mg, 82%):  Rf 0.47 (EtOAc); 1H NMR (500 MHz, DMSO-d6)  7.05 
(d, J = 8 Hz, 1H), 6.85 (s, 1H), 5.65 (dd, J = 2.5, 8 Hz, 1H), 4.08-4.04 (m, 1H), 3.61-
3.57 (m, 1H), 2.13-2.10 (m, 1H), 2.04-1.97 (m, 3H), 1.88-1.85 (m, 1H); 13C NMR (125 
MHz, DMSO-d6)  155.55, 127.34, 114.01, 106.77, 100.92, 76.78, 61.18, 45.22, 27.81, 
23.47.  Data matched that previously reported.28 
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Azide 97.  A solution of N,O-hemiacetal (93 mg, 0.27 mmol) and DBU (64 µL, 0.42 
mmol) in THF (10 mL) was treated with DPPA (92 µL, 0.42 mmol) and stirred at 22° C 
for 15 minutes.  The volatiles were removed under vacuum and the residue was purified 
by flash chromatography (SiO2, hexanes/EtOAc, 100:0  3:1  1:1  1:2) to provide 
azide 97 as a yellow solid which was contaminated with enamide 28: Rf 0.67 (EtOAc); 
1H NMR (500 MHz, acetone-d6) δ 6.89 (s, 1H), 5.83-5.85 (d, J = 9.5 Hz, 1H), 3.99 (m, 
1H), 3.64 (m, 1H), 3.50 (m, 1H), 1.92-2.20 (m, 4H); IR (neat, ATR) 2121, 1644, 1440. 
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Enamide 28.  Rf 0.62 (EtOAc); 1H NMR (500 MHz, acetone-d6) δ 7.20 (dt, J = 3, 3.5 
Hz, 1H), 7.04 (d, J = 1 Hz, 1H), 3.96 (t, J = 7 Hz, 2H), 3.07 (dt, J = 1.5, 7.5 Hz, 2H), 
2.24 (p, J = 7 Hz, 2H); 13C NMR (125 MHz, acetone-d6) δ 153.3, 133.8, 132.7, 130.2, 
110.8, 103.1, 101.2, 100.9, 47.50, 23.15; LRMS (APCI) calculated for C10H8N2OBr2 
331.9.  Found 331.1.  Data matched that previously reported.28 
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Hemi-aminal 98.  A solution of crude azide (93 mg, 0.27 mmol) in THF (3.0 mL) at 0° 
C was treated with PMe3 (0.70 mL, 0.66 mmol).  The mixture was stirred at 0 °C for 30 
minutes.  Then, H2O was added (1 equiv) and the mixture was refluxed for 1 h.  The 
volatiles were removed under vacuum and the residue was purified by flash 
chromatography (SiO2, hexanes/EtOAc, 100:0  3:1  1:1  1:2) to get hemi-aminal 
98 (44.7 mg, 48%) over 2 steps as an off-white solid:  Rf 0.15 (EtOAc);  1H NMR (500 
MHz, acetone-d6) δ 6.74 (s, 1H), 5.25 (d, J = 2.5 Hz, 1H), 4.17 (m, 1H), 3.61 (m, 1H), 
3.44 (m, 1H), 2.28 (m, 1H), 2.18 (m, 1H), 1.91 (m, 2H); IR (ATR, neat) 3319, 3278, 
1626; LRMS (ESI) calculated for C10H11Br2N3O [M+H] 350.0.  Found 349.9. 
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N-Tces hemi-aminal 99.  A solution of hemi-aminal (23.5 mg, 0.067 mmol) in pyridine 
(0.25 mL) at 0 °C was treated with Tces-Cl64 (33.4 mg, 0.135 mmol) added slowly down 
the wall of the reaction flask.  Solution went from colorless to almost red over several 
hours.  The reaction was allowed to warm-up to 22° C and stirred at 22° C for 6 h.  The 
volatiles were removed under vacuum and the residue was purified by flash 
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chromatography (SiO2, hexanes/EtOAc, 100:0  5:1  4:1  3:1  2:1  1:1  1:2) 
to provide sulfamate 99 (6.2 mg, 16%) as a yellow oil:  Rf 0.6 (EtOAc); 1H NMR (500 
MHz, acetone-d6) δ 6.81 (s, 1H), 6.09 (d, J = 3 Hz, 1H), 4.49-4.73 (AB, J = 11, 110 Hz, 
2H), 4.44 (m, 1H), 3.62 (m, 1H), 3.46 (m, 1H), 2.58 (d, J = 8 Hz, 1H), 2.38 (m, 2H), 
2.18 (m, 2H); LRMS (ESI) calculated for C12H12Br2Cl3N3O4S [M+H] 561.5.  Found 
561.8. 
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N-trichloroacetyl-N’-cyclohexylurea 101.  A solution of cyclohexylamine (115 L, 
1.00 mmol) in THF (5 mL) was treated with TAI (0.59 mL, 5.02 mmol).  The mixture 
was stirred at 22° C for 3 h.  The volatiles were removed under vacuum and the residue 
was purified by flash chromatography (SiO2, hexanes/EtOAc, 10:1) to provide N-
trichloroacetyl-N’-cyclohexylurea 101 as a white solid (230.6 mg, 80%):  Rf 0.5 
(hexanes/EtOAc, 6:1); 1H NMR (500 MHz, CDCl3) δ 8.96 (s, 1H), 7.81 (d, J = 6 Hz, 
1H), 3.72-3.78 (m, 1H), 1.96 (m, 2H), 1.73 (m, 2H), 1.61 (m, 1H), 1.23-1.44 (m, 5H); IR 
(ATR, neat) 3352, 3076, 1717, 1696, 1537, 1495; LRMS (APCI) calculated for 
C9H13Cl3N2O2 287.6.  Found 286.9. 
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Imidine 110.  A solution of hemi-aminal 98 (33.4 mg, 0.096 mmol), azeotroped with 
xylenes, in THF (0.5 mL) was treated with TAI (56.7 L, 0.478 mmol).  The mixture 
was stirred at 22° C overnight.  The volatiles were removed under vacuum and the 
residue was purified by flash chromatography (SiO2, hexanes/EtOAc, 1:1) to provide 
imidine 110 as a tan color solid (38.3 mg, 75%):  Rf 0.6 (EtOAc); 1H NMR (300 MHz, 
CDCl3) δ 9.03 (s, 1H), 8.34 (d, J = 9 Hz, 1H), 6.93 (s, 1H), 6.38-6.43 (dd, J = 3.3, 9.6 
Hz, 1H), 4.22 (m, 1H), 3.78 (m, 1H), 3.58 (m, 1H), 2.29 (m, 1H), 2.12 (m, 1H), 1.82-
2.02 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 161.7, 156.3, 150.4, 125.9, 116.4, 107.0, 
102.8, 60.80, 60.37, 44.69, 28.04, 23.28; IR (CH2Cl2) 1779, 1723, 1623, 1519; LRMS 
(ESI) calculated for C13H11Br2Cl3N4O3 537.4.  Found 537.8. 
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Isothiourea 104.  A pre-cooled solution at 0° C of imidochloride 10351b (34.7 mg, 0.108 
mmol) in CH2Cl2 (0.3 mL) was treated with a solution of hemi-aminal 98 (34.3 mg, 
0.098 mmol) in CH2Cl2 (0.5 mL), which was added dropwise followed by Et3N (16.4 
µL, 0.118 mmol).  The mixture was allowed to reach 22° C, and then the flask was 
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immersed in an oil bath at 55° C and stirred overnight.  The volatiles were removed 
under vacuum and the residue was purified by SiO2 column chromatography 
(hexanes/EtOAc, 3:1  1:1  1:2) to provide isothiourea 104 (41.5 mg, 67%) as a tan 
color solid:  Rf 0.65 (EtOAc); 1H NMR (500 MHz, acetone-d6) δ 8.24 (br s, 1H), 6.53 
(br s, 1H), 6.35 (br s, 1H), 4.53-4.52 (app s, 2H), 4.11 (br s, 1H), 3.36 (m, 1H), 3.11 (m, 
1H), 2.28 (s, 3H), 2.05 (m, 1H), 1.80 (m, 1H), 1.56-1.68 (m, 2H); 13C NMR (125 MHz, 
acetone-d6) δ 169.8, 156.1, 128.4, 114.9, 106.9, 102.0, 95.06, 79.68, 79.46, 63.69, 60.62, 
44.93, 23.74,  15.28; IR (neat, ATR) 3220, 1717, 1646, 1504, 1444, 1353, 1163; LRMS 
(ESI) calculated for C14H15Br2Cl3N4O4S2 [M+H] 634.6.  Found 634.8. 
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Guanidine 105.  A solution of isothiourea 104 (21.6 mg, 0.034 mmol) in THF (0.30 
mL) at room temperature (22° C) was treated with HgCl2 (10.2 mg, 0.037 mmol) 
followed by HMDS (18.5 µL, 0.085 mmol).  After stirring at 22° C for 5 h the mixture 
was filtered through Celite™, followed by wash with EtOAc, the volatiles were removed 
under vacuum.  The residue was purified by flash chromatography (SiO2, 
hexanes/EtOAc, 100:0  3:1  1:1  1:3) to provide guanidine 105 as a tan solid 
(19.3 mg, 94%).  Rf 0.35 (EtOAc/hexanes, 3:1); 1H NMR (500 MHz, acetone-d6) δ 8.03 
(d, J = 9 Hz, 1H), 6.91 (br s, 2H), 6.66 (s, 1H), 6.58 (d, J = 9.5 Hz, 1H), 4.75 (app t, J = 
13 Hz, 2H), 4.41 (m, 1H), 3.68 (m, 1H), 3.46 (m, 1H), 2.36 (m, 2H), 2.01-1.91 (m, 2   
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H); 13C NMR (125 MHz, acetone-d6) δ 157.44, 156.83, 126.58, 115.25, 107.28, 102.25, 
95.42, 78.86, 62.29, 61.36, 45.55, 28.34, 23.79; IR (neat, ATR) 3450, 3347, 1725, 1630, 
1535, 1444, 1305, 1175; LRMS (ESI) calculated for C13H14Br2Cl3N5O4S [M+H] 603.5.  
Found 603.8. 
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Table 8.  Crystal data and structure refinement for isothiourea 104. 
Identification code  dr53a 
Empirical formula  C14 H15 Br2 Cl3 N4 O4 S2 
Formula weight  633.59 
Temperature  110(2) K 
Wavelength  1.54184 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 8.634(4) Å α= 90°. 
 b = 17.310(7) Å β= 90°. 
 c = 29.935(12) Å γ = 90°. 
Volume 4474(3) Å3 
Z 8 
Density (calculated) 1.881 Mg/m3 
Absorption coefficient 9.913 mm-1 
F(000) 2496 
Crystal size 0.14 x 0.12 x 0.02 mm3 
Theta range for data collection 2.95 to 59.02°. 
Index ranges -7<=h<=8, -19<=k<=18, -22<=l<=33 
Reflections collected 15968 
Independent reflections 5728 [R(int) = 0.2080] 
Completeness to theta = 59.02° 91.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8264 and 0.3375 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5728 / 569 / 523 
Goodness-of-fit on F2 1.066 
Final R indices [I>2sigma(I)] R1 = 0.0736, wR2 = 0.1238 
R indices (all data) R1 = 0.1731, wR2 = 0.1660 
Absolute structure parameter -0.03(6) 
Largest diff. peak and hole 0.695 and -0.655 e.Å-3 
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Comments 
 
¼ molecule of C6H14 was found in the asymmetric unit.  The hexane was disordered 
between multiple positions and refinement of its positional parameters was not possible.  
Finally the electron density of the hexane was subtracted from the over data by 
employing the routine SQUEEZE in PLATON 2006 (see A.L.Spek (2005) PLATON, A 
Multipurpose Crystallographic Tool, Utrecht University, Utrecht, The Netherlands; 
A.L.Spek, J.Appl.Cryst. 2003, 36, 7-13).  After the subtraction the molecule was refined 
normally. 
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Table 9.  Crystal data and structure refinement for guanidine 105. 
Identification code  dr57 
Empirical formula  C14.50 H15.50 Br2 Cl3 N5 O4 S 
 C13 H12 Br2 Cl3 N5 O4 S  ¼(C6H14) 
Formula weight  622.05 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Trigonal 
Space group  P3(1)21 
Unit cell dimensions a = 18.533(13) Å α= 90°. 
 b = 18.533(13) Å β= 90°. 
 c = 25.13(2) Å γ = 120°. 
Volume 7474(10) Å3 
Z 12 
Density (calculated) 1.659 Mg/m3 
Absorption coefficient 3.688 mm-1 
F(000) 3678 
Crystal size 0.50 x 0.10 x 0.10 mm3 
Theta range for data collection 2.06 to 25.00°. 
Index ranges -22<=h<=21, -22<=k<=22, -29<=l<=29 
Reflections collected 51706 
Independent reflections 8676 [R(int) = 0.2213] 
Completeness to theta = 25.00° 99.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7093 and 0.2600 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8676 / 312 / 507 
Goodness-of-fit on F2 1.014 
Final R indices [I>2sigma(I)] R1 = 0.0724, wR2 = 0.1725 
R indices (all data) R1 = 0.1732, wR2 = 0.2221 
Absolute structure parameter 0.01(2) 
Largest diff. peak and hole 0.786 and -0.496 e.Å-3 
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